v3.26.1
Revenue Interest Obligation - (Details) - USD ($)
$ in Thousands
1 Months Ended 3 Months Ended
May 31, 2017
Oct. 31, 2025
May 31, 2025
Mar. 31, 2026
Mar. 31, 2025
Dec. 31, 2025
Jan. 10, 2024
Debt Instrument [Line Items]              
Current portion of revenue interest obligation       $ 5,500   $ 4,400  
Ligand Pharmaceuticals | Revenue Interest Obligation.              
Debt Instrument [Line Items]              
Present value of future minimum payments of obligation $ 27,700           $ 4,400
Percentage of future sales 5.00%            
Term of agreement 10 years            
Revenue interest obligation paid in shares     $ 2,200        
Issuance of common stock (in shares)     1,105,528        
Payment in satisfaction of the royalty obligation for the quarters ended June 30, 2025 and September 30, 2025   $ 2,200          
Revenue Interest Obligation recorded       100 $ 300    
Current portion of revenue interest obligation       5,500      
Amended Revenue Interest Obligation       4,400   $ 4,400  
Quarterly minimum unpaid       $ 1,100      
Cumulative sales of products exceed $300M | Ligand Pharmaceuticals | Revenue Interest Obligation.              
Debt Instrument [Line Items]              
Payments due based on cumulative sales $ 5,000            
Cumulative sales $ 300,000            
Milestone payment amount eliminated     $ 5,000